TriangleFOR PATIENTS · SOURCE READING
Targeted therapy
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Treatment Option Overview
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. There are different types of targeted therapy. These include:
Source links and citations
Tyrosine kinase inhibitor therapy: These inhibitors block signals that cancer cells need to grow and divide. Some tyrosine kinase inhibitors also have angiogenesis inhibitor effects. Tyrosine kinase inhibitors used to treat soft tissue sarcoma include pazopanib, imatinib, sunitinib, and regorafenib. New types of tyrosine kinase inhibitors are being studied, including cediranib and larotrectinib.
Histone methyltransferase inhibitor therapy: This therapy may help keep cancer cells from growing. Tazemetostat is a type of histone methyltransferase inhibitor therapy used to treat soft tissue sarcoma.
Source links and citations
For more information, see Drugs Approved for Soft Tissue Sarcoma.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice